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Summary The importance of polymorphism in the glutathione S-transferase GSTM1, GSTT1 and,
cytochrome P450, CYP2D6 loci in the pathogenesis of epithelial ovarian cancer has been assessed in two
studies; firstly, a case-control study designed to determine the influence of these genes on susceptibility to this
cancer, and secondly, the putative role of these genes in the protection of host cell DNA has been studied by
comparing p53 expression in patients with different GSTM1, GSTT1 and CYP2D6 genotypes. The frequencies
of GSTM1, GSTT1 and CYP2D6 genotypes in 84 cases and 325 controls were not different.
Immunohistochemistry was used to detect p53 expression in 63 of these tumours. Expression was found in
23 tumours. Of the patients demonstrating immunopositivity, 20 (87%) were GSTM1 null. The frequency
distributions of GSTM1 genotypes in p53-positive and -negative samples were significantly different (P=0.002)
and those for GSTT1 genotypes approached significance (exact P=0.057). The proportion of patients with
both GSTM1 null and GSTT1 null was also significantly greater in the immunopositive (4/22) than in the
immunonegative group (1/40) (P=0.0493). Single-strand conformational polymorphism (SSCP) analysis was
used to detect mutations in the 23 tumour samples demonstrating p53 positivity. A shift in electrophoretic
mobility of amplified fragments was found in 11 patients (exons 5, 6, 7 and 8) and these exons were sequenced.
In eight samples a mutation was found. No SCCP variants were identified in the other 12 immunopositive
patients. Sequencing of exons 4-9 of p53 from these tumours resulted in the detection of mutations in two
patients (exons 5 and 7). Thus, in 23 patients who demonstrated immunopositivity, p53 mutations were found
in nine patients with GSTM1 null (90.0%). In the 13 patients in whom no mutations were identified, 11 were
GSTM1 null (84.6%). The data show that overexpression of p53 is associated with the GSTM1 null genotype.
We propose the data are compatible with the view that GSTM1 and GSTT1 are critical in the detoxification of
the products of oxidative stress produced during the repair of the ovarian epithelium. Thus, failure to detoxify
products of this stress may result in damage to various genes in the host cell, including to p53, resulting in
persistent expression of mutant protein. In other patients, oxidative stress effects damage to various genes, but
not including p53, resulting in overexpression of wild-type p53.
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Epithelial ovarian cancer is the primary cause of gynaecolo-
gical cancer death in the western world. No single causative
factor has been identified and over 90% of cases occur
sporadically. Risk increases with age, family history and
incessant ovulation (Goodwin et al., 1993). The cells of the
ovarian surface epithelium have important functions during
reproductive life and undergo rapid cycles of cell division
during repair of ovulation trauma (Goodwin et al., 1993),
suggesting involvement of reactive oxygen species (ROS).
Individual cancer risk depends on various factors, including
detoxification of carcinogens. Accordingly, there is much
interest in the significance of polymorphism in the
cytochrome P450 (CYP) and glutathione S-transferase
(GST) supergene families, as these enzymes metabolise
exogenous and endogenous molecules involved in cell-
specific functions, such as proliferation and apoptosis
(Nebert, 1994). Thus, alleles associated with inappropriate
detoxification appear promising candidates for cancer risk
(Wolf et al., 1992; Bell et al., 1993; Heagerty et al., 1994;
Elexpuru-Camiruaga et al., 1995). Mu and theta class GST
appear important in the detoxification of products of
oxidative stress, such as lipid hydroperoxides, alkenals and
DNA hydroperoxides, as well as potential carcinogens, such
as methyl halides and benzo(a)pyrene epoxides (Smith et al.,
1995; Strange, 1996). Both the mu class, GSTMI, and theta
class, GSTTI, genes are polymorphic with null alleles (Smith
et al., 1995; Strange, 1996). GSTMI*O homozygotes appear
more susceptible to various pathologies, including skin and
bladder cancers (Heagerty et al., 1994; Bell et al., 1993), while
homozygosity for GSTTI*O is associated with increased risk
of colorectal cancer and brain tumours (Smith et al., 1995;
Elexpuru-Camiruaga et al., 1995; Deakin et al., 1996). The
function of CYP2D6 is unclear, although data showing
allelism influences susceptibility to brain tumours, Parkin-
son's disease and multiple basal cell carcinomas of skin
suggest its importance in detoxification (Smith et al., 1995;
Elexpuru-Camiruaga et al., 1995; Heagerty et al., 1996).
While accumulating evidence implicates GST and CYP as
determinants of cancer risk, it is unknown why genotypes
appear significant in some cancers but not others. These
enzymes demonstrate broad substrate specificities and certain
genotypes, alone or in combination, may identify detoxifica-
tion-deficient subjects, who are more likely to suffer
particular mutations in target genes, such as p53 (Perrett et
al., 1995; Ryberg et al., 1994). Various studies show genetic
change in ovarian tumours with loss of heterozygosity (LOH)
found on most chromosomes, including 17p. This segment,
on which p53 resides, shows LOH in 60% ovarian cancers,
whereas 17q and 18q show loss in excess of 30% (Eccles et
al., 1992a, b; Sheriden et al., 1994). Clearly, ovarian cancer
patients are a heterogenous group described by different
mutations, possibly because of differences in genetically
mediated ability to detoxify mutagens. An understanding of
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why certain mutations occur should help elucidate the causes
of this cancer and may identify prognostic markers.
Accordingly, we have assessed the role of GSTM1, GSTT1
and CYP2D6 genotypes in determining susceptibility to
ovarian cancer. The relationship between allelism at these
loci and expression of p53 has been studied using
immunohistochemical identification of the protein with
single-strand confirmational polymorphism analysis (SSCP)
and sequencing of exons 4-9 of the p53 gene.
Materials and methods
Patients
A total of84 unrelated, northern European Caucasian women
(median age 59 years) with histologically confirmed epithelial
ovarian cancer were recruited, with Ethics Committee approval
and informed consent, in the North Staffordshire Hospital
during 1993-94. They represented almost all new cases treated
in hospital during this period. Information on patient
demographics, disease, treatment and response was recorded.
No patients received othertreatment before surgery. Theywere
staged by the criteria of the International Federation of
Gynaecologists and Obstetricians (FIGO) (Shepherd, 1989)
(Table I). Histological type and grade were assigned by a
pathologist (CM,VS). Blood (5 ml) was collected in EDTA
from all patients, paraffin-embedded tumour samples were
available for 64 of these cases. Genotype frequencies were
compared with those of 325 unrelated, Caucasian female
controls. Thisgroup included 232women (medianage 53 years)
undergoing hysterectomy and bilateral salpingoophorectomy
for benign disease (menorrhagia and pelvic inflammatory
disease). Paraffin-embedded ovarian tissue was obtained from
20 ofthesewomen. Othercontrols suffered benign breastlumps
and mild iron deficiency.
Identification of GSTMI, GSTTI, CYP2D6 genotypes in
leucocyte DNA
Primer sets to intron 6/exon 7 of GSTM1 were used in a
polymerase chain reaction (PCR) to identify GSTMI*O/
GSTMJ*O, GSTMJ*AIGSTM1*B and GSTM1 A and
GSTM1 B (Elexpuru-Camiruaga et al., 1995). GSTTl null
and expressing subjects were identified using PCR amplifica-
tion (Elexpuru-Camiruaga et al., 1995). Two mutant
CYP2D6 alleles (G-A transition at intron 3/exon 4 and
exon 5 base pair deletion) were identified. Together these
assays are approximately 90% predictive of phenotype in
British Caucasians (Wolf et al., 1992; Smith et al., 1995).
Table I Characteristics of epithelial ovarian cancer patients
FIGO stage
I
II
III
IV
Total
Grade
l
2
3
Total
Histological type
Serous
Mucinous
Endometrioid
Clear cell
Anaplastic
Total
24 (28.0%)
5 (6.0%)
48 (58.0%)
7 (8.0%)
84 (100%)
19 (23.0%)
22 (26.0%)
43 (51.0%)
84 (100%)
36 (43.0%)
12 (14.0%)
14 (17.0%)
6 (7.0%)
16 (19.0%)
84 (100%)
Immunohistochemistry ofp53 protein
p53 protein was identified in paraffin embedded sections
from 64 cases and 20 controls using two p53 antibodies;
rabbit polyclonal CM-1 diluted 1:100 and monoclonal
antibody DO-7 diluted 1:500 in phosphate-buffered saline
(PBS) (Perrett et al., 1995). A grade III breast carcinoma
was used as positive control, while omission of primary
antibody served as a negative control. Sections (5 jgm) were
incubated with the antisera. Secondary antibodies, biotiny-
lated swine anti-rabbit immunoglobulins for CM-1, or
biotinylated anti-mouse antibody for DO-7, were also
used. Sections were deemed to be p53 positive if over
50% of nuclei in tumour cells demonstrated strong
expression.
Analysis of exons 4-9
Exons4-9 ofp53 in tumourDNA from immunohistochemical
positive sections were analysed using SSCP and sequencing.
Neoplastic tissuewas removed from unstained sections under a
dissectingmicroscope using a serial haematoxylin/eosin section
as a template guide. This minimised mixing of normal and
tumourcells. DNA was extracted by digesting sections (37°C, 5
days) with 50 mM Tris, pH 8.5, 1 mM EDTA, 0.5% Tween 20,
0.2 mgml- I proteinase K. Each extraction yielded DNA for 50
amplifications. Primers that amplified exons 5-9 (one primer
pair) or exon 4 (two overlapping primer pairs) were used to
facilitate SSCP analysis (maximum size 250 bases). Primers
encompassed exon-intron boundaries. The PCR comprised
primers (5 gM), 0.2 mM deoxynucleotides, 1 U Taq DNA
polymerase with 10 x PCR buffer containing 15 mM magne-
sium chloride and 250 ng DNA. In some cases, 0.3 uCi
[32P]dATP (Amersham Life Sciences) was used. PCR for
exons 5, 6 and 8 involved denaturation (94°C, 2.5 min) and
35 cycles of93°C (1 min), 57°C (1 min) and 72°C (1 min), with
a final extension at 72°C (2 min). Annealing temperature for
exon 7 was 59°C. Exons 4 and 9 included final extension (72°C,
5 min).
SSCP analysis
DNA from immunohistochemically positive samples (using
one or both antibodies) was first screened by SSCP analysis
of exons 4-9 in an attempt to identify exons containing
mutations and, thereby, reduce the number of exons that
required sequencing. Thus, usually one exon was sequenced.
Immunohistochemistry-positive but SSCP-negative samples
were sequenced across exons 4-9. For SSCP, 5 Ml PCR
product was mixed with S jil 95% formamide, 10 mm sodium
hydroxide, 20 mM EDTA, 0.1% bromophenol blue and 0.1%
xylene cyanol, heated (100°C, S min) and placed on ice.
Samples were applied to 5% polyacrylamide gels containing
90 mM Tris-borate, pH 8.2, 2.5 mM EDTA (TBE). Dena-
tured sample containing [32P]dATP was loaded onto two gels
and run at 25 W at 4°C or 20°C for 4.5 h. For exon 7, non-
radioactive denatured sample was loaded onto gels (20 cm,
20 cm and 1 mm) and run at 25 mA (3 h, 16°C). For other
exons, denatured sample was loaded onto two gels (49 cm,
17 cm and 1 mm) and run (5.5 h, 30 W) at 4°C or 20°C. Gels
were silver stained and fixed in 10% ethanol, 0.5% acetic acid
(7 min), followed by 0.1% aqueous silver nitrate. Positive
controls were DNA from cell lines with mutated p53.
Leucocyte DNA from each patient served as a negative
control.
DNA sequencing ofPCR products
Tumour DNA from immunohistochemically positive samples
was amplified using primers that encompassed the intron/exon
boundaries for each exon. One primer was biotinylated and
isolated using streptavidin-coated magnetic beads (Dynal UK
Ltd). The resulting single-stranded DNA was used as the
template using the Sequenase Version 2.0 (USB, AmershamAllelism in detoxifying enzymes and susceptibility to ovarian cancer
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Life Sciences). Internal sequencing primers were used for each
exon and sequences were analysed on 6% polyacrylamide gels.
The initial PCR amplification and sequencing reactions were
repeated at least once to confirm data and in some cases both
strands of the template were anlaysed. Exon 4 was analysed in
two halves with non-overlapping internal primers. In the two
samples that demonstrated SSCP variants, but in which no
mutations were detected, the complementary DNA strand was
also sequenced. Primer sequences are available on request.
Results
GST and CYP genotype frequencies in patients with ovarian
cancer
Table II shows the frequencies of GSTM1, GSTT1 and
CYP2D6 genotypes in controls and the 84 patients with
ovarian cancer. No significant differences in genotype
frequencies or frequency distributions between these groups
were identified.
Immunohistochemical identification ofp53 expression
Sections from controls and patients with ovarian cancer were
examined using the two p53 antibodies; 23 of the 63 patients
(36.5%) were positive using the CM-1 antibody. In 11 of
these patients, 50-75% of tumour cell nuclei stained
positively for p53, while in the remaining 12, 75-100% of
tumour nuclei were positive. Of these 23 patients, 18
demonstrated positivity using both CM-1 and DO-7 (Tables
II and III). No cases of DO-7 positivity but CM-I negativity
were identified. All samples from controls were negative for
p53 using both antibodies.
All tumour samples demonstrating p53 positivity were
stage III or IV and grade 2 or 3. We did not observe a
significant difference in primary response to chemotherapy
with carboplatin between p53-positive and -negative cases.
We also found no significant difference in histological type
between p53-positive and -negative samples.
Comparison of enzyme genotypes in immunohistochemi-
cally positive and negative cases showed 20/23 CM-1-positive
Table II GSTM1, GSTT1 and CYP2D6 genotype frequencies in controls and patients with epithelial ovarian cancer
GSTMIA GSTMIB GSTMIA/B GSTMInull
Controls (n= 312) 71 (22.8%) 41 (13.1%) 8 (2.6%) 192 (61.5%)
Ovarian cancer (n=84) 20 (23.8%) 12 (14.3%) 5 (6.0%) 47 (55.9%)
p53 positive CM-I (n=23) 1 (4.3%) 2 (8.7%) 0 (0%) 20 (87.0%)
p53 negative (n=40) 14 (35.0%) 6 (15.0%) 4 (10.0%) 16 (40.0%)
GSTT1 null GSTT1 positive
Controls (n=325) 61 (18.8%) 264 (81.2%)
Ovarian cancer (n =81) 13 (16.0%) 68 (84.0%)
p53 positive CM-1 (n=22) 6 (27.3%) 16 (72.7%)
p53 negative (n=40) 3 (7.5%) 37 (92.5%)
CYP2D6 EM CYP2D6 HET CYP2D6PM
Controls (n=280) 177 (63.2%) 89 (31.8%) 14 (5.0%)
Ovarian cancer (n=83) 49 (59.0%) 29 (34.9%) 5 (6.0%)
p53 positive CM-1 (n=23) 11 (47.8%) 11 (47.8%) 1 (4.3%)
p53 negative (n=40) 28 (70.0%) 9 (22.5%) 3 (7.5%)
Data shows genotype frequencies in controls, the total ovarian cancer case group and in the patients with ovarian cancer who demonstrated p53
immunopositivity and immunonegativity.
Table III GSTM1 genotypes, p53 immunoreactivity and DNA sequencing data in patients with ovarian cancer
Predicted
GSTMI GSTTI CM-] SSCP Mutant Nucleotide amino acid Transitnl
genotype genotype /DO-7 exon codon change change transvsa
1. Ml 0 TIA +/+ ExonS 168 A-C/A HIS-PRO/HIS Transvs
2. MIO TIA +/+ ExonS 179 C-T HIS-TYR Transitn
3. MI0 TIA +/+ Exon5 141 G-A/G CYS-TYR/CYS Transitn
4. MIO TIO +/+ ExonS 135 G-A CYS-TYR Transitn
5. MIO TIO +/+ Exon6 None
6. MIA TIA +/+ Exon7 248 G-A ARG-GLN Transitn
7. M1O TIA +/- Exon7 None
8. M10 TIA +/+ Exon7 None
9. MiO TIA +/+ Exon8 267 G-C ARG-PRO Transvs
269 A-T SER-CYS
10. Mi 0 +/+ Exon8 273 G-T ARG-LEU Transvs
11. Ml0 TIA +/+ Exon8 284 A-C THR-PRO Transitn
12. MI 0 TIA +/+ Negative 241 C-T/C SER-PHE/SER Transitn
13. MI0 TIA +/- Negative None
14. MIO T10 +/+ Negative None
15. MIB TIA +/+ Negative None
16. MIB TIO +/+ Negative None
17. M10 TIA +/+ Negative None
18. MI0 TIA +/- Negative None
19. Ml 0 TIA +/- Negative 163 A-G/A TYR-CYS/TYR Transitn
20. M1O TIA +/+ Negative None
21. MIA TIO +/+ Negative None
22. M10 TIO +/- Negative None
23. Ml0 TIA +/+ Negative None
aTransitn, transition; transvs, transversion.Allelism in detoxifying enzymes and susceptibility to ovarian cancer
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cases (87.0%) and 15/18 CM-1- and DO-7-positive cases
(83.3%) were GSTM1 null (Tables II and III). Two of the
other cases were GSTM1 B and one GSTM1 A. GSTM1
phenotypes in the 40 patients who demonstrated negativity for
p53 are also shown in Table II. The frequency distributions of
GSTM1 genotypes in the p53-positive and -negative subjects
were significantly different (X23 = 14.15, exact P= 0.002). The
frequency distributions ofGSTT1 genotypes in the p53-positive
and -negative samples are also shown in Tablell; the difference
between these approached significance (x2, =4.472, exact
P=0.057). The number of patients with both the GSTM1
null and GSTT1 null genotypes was significantly greater in the
immunopositive (4/22) than in the immunonegative group (1/
40) (X2,=4.708; P=0.0493). For CYP2D6, the corresponding
proportions in the p53-positive cases were: CYP2D6 PM, 1/23
(CM-1) and 1/18 (CM-1 and DO-7). Frequencies of CYP2D6
genotypes in p53-positive and -negative subjects were not
significantly different.
SSCP and DNA sequencing studies
Table III shows the results of SSCP analysis of exons 4-9 of
ovarian tumour DNA from the 23 patients who demonstrated
immunohistochemical positivity for p53. A shift in the
electrophoretic mobility of amplified fragments was identified
in 11 patients in exons 5, 6, 7 or 8 and, in each case, this exon
was sequenced. In eight of these 11 patients a mutation was
found in the abnormallymigrating exon, while in the remaining
three patients no mutations were found. In 12 of the patients
who demonstrated immunohistochemical positivity, no elec-
trophoretic variants were identified by SSCP. Sequencing of
exons 4-9 of p53 in tumour DNA from these SSCP-negative
patients resulted in the detection of mutations in DNA from
two patients (exons 5 and 7). No mutations were found in DNA
from the remaining ten patients (Table III). Thus, in the total
group of 23 patients who demonstrated immunopositivity,
mutations in p53 were found in ten patients. Nine ofthese cases
were GSTM1 null (90.0%). In the group of 13 patients inwhom
no mutations were identified, 11 patients were GSTM1 null
(84.6%).
Table III shows the mutations and their corresponding
codons found in ten of the 23 patients who demonstrated
immunopositivity for p53. All mutations were missense with
seven of the ten being transitions and three transversions. In
four of ten tumours, both a normal and mutant allele were
detected and in one case we found a mutation occurring in
two separate codons (267 and 269) of p53 DNA from the
same tumour.
Discussion
We have studied the influence of polymorphism in GSTM1,
GSTT1 and CYP2D6 on susceptibility to epithelial ovarian
cancer in, firstly, a case-control study of genotype
frequencies in patients with ovarian cancer and comparable
controls, and secondly, in a study of the relationship between
allelism and p53 expression. We studied protein expression
using two antibodies and, in cases demonstrating immuno-
histochemical positivity, identified mutations by sequencing
exons 4-9 of the gene in DNA from tumour material.
While the causes of ovarian cancer are unclear, the
importance of ROS generated during repair of ovulation-
induced damage to the ovarian surface epithelium is worthy of
consideration (Goodwin et al., 1993). Increased expression of
p53 is likely during such oxidant stress, as DNA damage is an
early consequence of exposing cells to even apparently
physiological concentrations of hydrogen peroxide, presum-
ably because ofintranuclear formation of"OH. Thus, Spragg et
al (1991) showed DNA strand breaks, 15 -30 min after
exposing endothelial cells to 5 x 10' M hydrogen peroxide.
Studies in isolated glomeruli also showed significant pyknosis,
karyohexis or karyolysis after incubation with hydrogen
peroxide concentrations as low as 4.7 x 10'8 M (Clayton et
al., 1992). The putative role of oxidative stress in the
pathogenesis ofovarian cancer suggests the importance ofthe
GST supergene family (Strange, 1996). The isoforms encoded
by GSTM1 and GSTT1 catalyse the detoxification ofgenotoxic
chemicals, including oxidised lipid and DNA products of
inflammatory stress (Strange, 1996). Homozygotes for
GSTMI*O and GSTTI'O appear at increased risk of
cytogenetic damage as assessed by sister chromatid exchange,
and these genotypes occur with increased frequency in several
cancer case groups (Smith et al., 1995; Strange, 1996). We
found the frequencies of GSTM1 and GSTT1 genotypes in
patients with ovarian cancer were not different to those in
controls, although the frequency of GSTM1 null was
significantly associated with p53 immunopositivity; 20/23 of
the immunopositive samples were GSTM1 null. Similarly,
while not quite achieving significance, the frequency ofGSTT1
null appeared greater in patients demonstrating immunoposi-
tivity (6/22). Furthermore, the frequency of the GSTM1 null/
GSTT1 null haplotype was significantly increased in the
immunopositive (4/22) compared with immunonegative
samples (1/40). This is apparently the first report ofsignificant
interactions between these genotypes.
The p53 gene is an important target in studies assessing the
consequences of allelism in carcinogen-metabolising enzymes,
as over 50% of malignant tumours of different types have
mutations or rearrangements of this gene (Greenblat et al.,
1994). Thus, inappropriate expression is found in about 50% of
ovarian cancers (Eccles et al., 1992a, b; Sheriden et al., 1994)
with studies showing a close correlation with loss of
heterozygosity close to the gene; 11 of 12 tumours demonstrat-
ing immunohistochemical positivity showed LOH at 17p at the
nearest informative locus to the gene. We found positivity in
36% of tumour samples examined, although as expected from
published data, mutations in exons 4-9 were not identified in
all of these samples (Greenblat et al., 1994); we found
mutations in only ten of 23 immunohistochemically positive
tumours. Further, we sequenced exon-intron boundaries and
found no sequence variants that would delete specific exons.
We interpret these data as indicating that many ofthe ovarian
tumours studied may overexpress wild-type p53. This view is
supported by studies in a variety ofcancers, in which the entire
coding region of p53 has been sequenced, showing 87% of
mutations are in exons 5-8 with a further 8% in exon 4
(Greenblat et al., 1994). We recognise that these data, like our
own, are based on sequencing within coding regions of the
gene, implying they provide an underestimate ofthe frequency
ofmutations, as some occur in promoter or intronic sequences.
However, this possibility appears uncommon and has not been
fully evaluated in any tumour (Greenblat et al., 1994).
Our data show, as expected, that patients with epithelial
ovarian cancer are heterogeneous in the molecular lesions
associated with carcinogenesis. In this study, some patients
did not express p53 protein (although the p53 gene may carry
mutations in some of these samples), others expressed
persistent, mutant protein, while others appeared to over-
express detectable wild-type protein. Expression of p53,
detectable by immunohistochemistry, was significantly
associated with GSTM1 null. We propose this observation
reflects the critical role of GSTM1 in the detoxification of the
products of oxidative stress, a view supported by studies in
patients with various pathologies (Strange, 1996). For
example, in patients suffering systemic lupus erythematosus,
GSTM1 null is associated with the photosensitivity
characterised by the production of anti-Ro (but not anti-
La) antibodies (Ollier et al., 1996). Thus, in the ovary,
chronic failure to detoxify the lipid and/or DNA products of
the process of repair of the ovarian epithelium effectively may
result in damage to various genes in host cells. In some
patients, the p53 gene is also damaged, resulting in persistent
expression of mutant protein. In other patients, the oxidative
stress effects damage to various genes not including p53,
resulting in overexpression of wild-type p53. The factors
determining which host genes are damaged are unknown. The
complexity of the ovarian cancer group is also shown by theAllelism in detoxifying enzymes and susceptibility to ovarian cancer
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finding that in our series, 40/63 tumours did not demonstrate
p53 immunopositivity. This suggests that other tumour-
suppressor genes are involved. Clearly, a better under-
standing of the influence of GSTM1 and other polymorphic
carcinogen-metabolising enzymes on mutational events could
have important implications in disease prognosis or
prevention.
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